These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 34713386)

  • 1. Initiating Opioid Use Disorder Medication via Telemedicine During COVID-19: Implications for Proposed Reforms to the Ryan Haight Act.
    Huskamp HA; Riedel L; Uscher-Pines L; Busch AB; Barnett ML; Raja P; Mehrotra A
    J Gen Intern Med; 2022 Jan; 37(1):162-167. PubMed ID: 34713386
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of telemedicine for opioid use disorder treatment - Perceptions and experiences of opioid use disorder clinicians.
    Riedel L; Uscher-Pines L; Mehrotra A; Busch AB; Barnett ML; Raja P; Huskamp HA
    Drug Alcohol Depend; 2021 Nov; 228():108999. PubMed ID: 34517225
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Telemedicine Use and Quality of Opioid Use Disorder Treatment in the US During the COVID-19 Pandemic.
    Hailu R; Mehrotra A; Huskamp HA; Busch AB; Barnett ML
    JAMA Netw Open; 2023 Jan; 6(1):e2252381. PubMed ID: 36692880
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of opioid use disorder during COVID-19: Experiences of clinicians transitioning to telemedicine.
    Uscher-Pines L; Sousa J; Raja P; Mehrotra A; Barnett M; Huskamp HA
    J Subst Abuse Treat; 2020 Nov; 118():108124. PubMed ID: 32893047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Telehealth for opioid use disorder treatment in low-barrier clinic settings: an exploration of clinician and staff perspectives.
    Aronowitz SV; Engel-Rebitzer E; Dolan A; Oyekanmi K; Mandell D; Meisel Z; South E; Lowenstein M
    Harm Reduct J; 2021 Nov; 18(1):119. PubMed ID: 34823538
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-Term Prospects for Telemedicine in Opioid Use Disorder (OUD) Treatment: Results from a Longitudinal Survey of OUD Clinicians.
    Huskamp HA; Riedel L; Campa I; Busch AB; Rose S; Mehrotra A; Uscher-Pines L
    J Gen Intern Med; 2023 Jul; 38(9):2139-2146. PubMed ID: 36964424
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characteristics and correlates of U.S. clinicians prescribing buprenorphine for opioid use disorder treatment using expanded authorities during the COVID-19 pandemic.
    Jones CM; Diallo MM; Vythilingam M; Schier JG; Eisenstat M; Compton WM
    Drug Alcohol Depend; 2021 Aug; 225():108783. PubMed ID: 34049102
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-Threshold Buprenorphine via Community Partnerships and Telemedicine-Case Reports of Expanding Access to Addiction Treatment During COVID-19.
    Levander XA; Wheelock H; Pope J; Lee A; Hartmann K; Abuelkhair S; Gregg JL; Buchheit BM
    J Addict Med; 2022 Jan-Feb 01; 16(1):e56-e58. PubMed ID: 34374502
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Health center implementation of telemedicine for opioid use disorders: A qualitative assessment of adopters and nonadopters.
    Uscher-Pines L; Raja P; Mehrotra A; Huskamp HA
    J Subst Abuse Treat; 2020 Aug; 115():108037. PubMed ID: 32600625
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Implementing a low-threshold audio-only telehealth model for medication-assisted treatment of opioid use disorder at a community-based non-profit organization in Washington, D.C.
    Yeo EJ; Kralles H; Sternberg D; McCullough D; Nadanasabesan A; Mayo R; Akselrod H; Catalanotti J
    Harm Reduct J; 2021 Dec; 18(1):127. PubMed ID: 34886850
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Buprenorphine implementation at syringe service programs following waiver of the Ryan Haight Act in the United States.
    Lambdin BH; Bluthenthal RN; Tookes HE; Wenger L; Morris T; LaKosky P; Kral AH
    Drug Alcohol Depend; 2022 Aug; 237():109504. PubMed ID: 35688052
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of and Retention on Video, Telephone, and In-Person Buprenorphine Treatment for Opioid Use Disorder During the COVID-19 Pandemic.
    Frost MC; Zhang L; Kim HM; Lin LA
    JAMA Netw Open; 2022 Oct; 5(10):e2236298. PubMed ID: 36223118
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Response to coronavirus 2019 in Veterans Health Administration facilities participating in an implementation initiative to enhance access to medication for opioid use disorder.
    Gustavson AM; Gordon AJ; Kenny ME; McHenry H; Gronek J; Ackland PE; Hagedorn HJ
    Subst Abus; 2020; 41(4):413-418. PubMed ID: 32936695
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The COVID-19 pandemic and opioid use disorder: Expanding treatment with buprenorphine, and combining safety precautions with telehealth.
    Cales RH; Cales SC; Shreffler J; Huecker MR
    J Subst Abuse Treat; 2022 Feb; 133():108543. PubMed ID: 34210567
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characteristics of US Counties With High Opioid Overdose Mortality and Low Capacity to Deliver Medications for Opioid Use Disorder.
    Haffajee RL; Lin LA; Bohnert ASB; Goldstick JE
    JAMA Netw Open; 2019 Jun; 2(6):e196373. PubMed ID: 31251376
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Understanding opportunities and challenges with telemedicine-delivered buprenorphine during the COVID-19 pandemic.
    Mattocks KM; Moore DT; Wischik DL; Lazar CM; Rosen MI
    J Subst Abuse Treat; 2022 Aug; 139():108777. PubMed ID: 35346533
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mobile Telemedicine for Buprenorphine Treatment in Rural Populations With Opioid Use Disorder.
    Weintraub E; Seneviratne C; Anane J; Coble K; Magidson J; Kattakuzhy S; Greenblatt A; Welsh C; Pappas A; Ross TL; Belcher AM
    JAMA Netw Open; 2021 Aug; 4(8):e2118487. PubMed ID: 34448869
    [TBL] [Abstract][Full Text] [Related]  

  • 18. COVID-19 Adaptations in the Care of Patients with Opioid Use Disorder: a Survey of California Primary Care Clinics.
    Caton L; Cheng H; Garneau HC; Fisher T; Harris-Mills B; Hurley B; Newman S; McGovern MP
    J Gen Intern Med; 2021 Apr; 36(4):998-1005. PubMed ID: 33511572
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early innovations in opioid use disorder treatment and harm reduction during the COVID-19 pandemic: a scoping review.
    Krawczyk N; Fawole A; Yang J; Tofighi B
    Addict Sci Clin Pract; 2021 Nov; 16(1):68. PubMed ID: 34774106
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 'Red Flags' and 'Red Tape': Telehealth and pharmacy-level barriers to buprenorphine in the United States.
    Textor L; Ventricelli D; Aronowitz SV
    Int J Drug Policy; 2022 Jul; 105():103703. PubMed ID: 35561484
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.